284 related articles for article (PubMed ID: 34759011)
1. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling.
Taylor RE; Bhattacharya A; Guo GL
Drug Metab Dispos; 2022 Apr; 50(4):456-467. PubMed ID: 34759011
[TBL] [Abstract][Full Text] [Related]
2. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
4. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.
Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D
Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893
[TBL] [Abstract][Full Text] [Related]
5. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
6. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
Zhou W; Anakk S
Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
[TBL] [Abstract][Full Text] [Related]
7. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
8. Bile Acids and FXR: Novel Targets for Liver Diseases.
Stofan M; Guo GL
Front Med (Lausanne); 2020; 7():544. PubMed ID: 33015098
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
Liu X; Wang J; Li M; Qiu J; Li X; Qi L; Liu J; Liu P; Xie G; Wang X
J Gastroenterol Hepatol; 2023 Aug; 38(8):1438-1446. PubMed ID: 37415275
[TBL] [Abstract][Full Text] [Related]
10. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease.
Liu Y; Liu T; Zhao X; Gao Y
Cell Mol Life Sci; 2022 Aug; 79(9):486. PubMed ID: 35978227
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
13. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
[TBL] [Abstract][Full Text] [Related]
14. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
[TBL] [Abstract][Full Text] [Related]
15. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
16. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.
Kumari A; Pal Pathak D; Asthana S
Int J Biol Sci; 2020; 16(13):2308-2322. PubMed ID: 32760200
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
[TBL] [Abstract][Full Text] [Related]
18. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
Sun L; Cai J; Gonzalez FJ
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
[TBL] [Abstract][Full Text] [Related]
19. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
